SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-23-000066
Filing Date
2023-11-06
Accepted
2023-11-06 08:06:09
Documents
54
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20230930.htm   iXBRL 10-Q 1129501
2 EX-31.1 exhibit311q32023.htm EX-31.1 17235
3 EX-31.2 exhibit312q32023.htm EX-31.2 17116
4 EX-32.1 exhibit321q32023.htm EX-32.1 9852
  Complete submission text file 0001664710-23-000066.txt   4311311

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20230930.xsd EX-101.SCH 27973
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20230930_cal.xml EX-101.CAL 49608
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20230930_def.xml EX-101.DEF 94715
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20230930_lab.xml EX-101.LAB 448607
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20230930_pre.xml EX-101.PRE 271060
48 EXTRACTED XBRL INSTANCE DOCUMENT kros-20230930_htm.xml XML 316188
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 231378181
SIC: 2834 Pharmaceutical Preparations